Recombinant human interferon-β (rhIFN-β) used clinically has lower efficacy than expected due to protein instabilities such as aggregation. Increasing molecular stability, glycoengineering has been used to improve clinical efficacy for a number of therapeutics; however, often laborintensive trail-and-error approaches are used to identify additional glycosylation sites. In this study two rhIFN-β analogs with one additional glycosylation site, L6T and S75N, identified by a rational in silico approach, were characterized. These rhIFN-β analogs were synthesized in parallel with a Chinese hamster ovary (CHO) codon-optimized natural human IFN-β (Opt-IFN-β) and expressed in CHO cells using the same expression system. The molecular weights for both analogs were observed to be higher than Opt-IFN-β, consistent with hyper-glycosylation. The in vitro biological assay showed the hyper-glycosylated analogs and the Opt-IFN-β had similar activity. The aggregation studies demonstrated that both analogs had lower tendencies to aggregate compared to the Opt-IFN-β. These experimental studies validate the in silico strategy to predict suitable glycosylation sites that would be glycosylated, while maintaining biological function. Moreover, this work describes hyper-glycosylated rhIFN-β analogs with improved solubility (i.e. lower aggregation). These findings, together with the rational in silico design, will allow us to increase protein glycosylation with the goal to enhance therapeutic efficacy.
Introduction
Human interferon-β (hIFN-β) belongs to the Type I interferon family (Pestka, 2007) . It is a 166 amino acid glycoprotein with a nonglycosylated molecular weight of 18 kDa. The single native N-linked glycan of Asn-80 can increase the molecular weight to between 23 and 25 kDa (Karpusas et al., 1997; Runkel et al., 1998) . Due to hIFN-β cytokine activity, it is used clinically to treat disease, such as hepatitis and multiple sclerosis (MS) (Festi et al., 2004, Rudick and Goelz, 2011) . Commercially, a recombinant glycosylated form, IFN-β la, is produced in Chinese hamster ovary (CHO) cells and a non-glycosylated form, IFN-β lb, is produced in Escherichia coli. IFN-β la is more potent and has higher specific activity compared to IFN-β lb due to the stability effect of the attached glycan. . Nevertheless, therapeutic usages of the IFN-β 1a are limited due to its high aggregation (Rodriguez et al., 2010; van Beers et al., 2010) . Protein aggregation is arguably the most common and troubling manifestation of protein instability encountered in almost all stages of protein drug development. It limits therapeutic efficacy due to the development of immunogenic response and/or pharmacokinetic issues (Jing et al., 2012) . For example, aggregated rhIFN-β elicits undesirable immune responses including neutralizing antibodies (NAbs) in the serum, which are a major problem in MS patients treated with the IFN-β 1a (Romero Lopez and Macineiras Montero, 2005; Sorensen, 2008) . Production and storage of rhIFN-β also cause protein aggregation challenges, where aggregation predominantly is due to the hydrophobic interactions between exposed peptide residues located on the protein surface (Rodriguez et al., 2010) .
Glycan moieties play an important role in molecular stability and in vivo biological activity by increasing the size and charge of protein (Li and d'Anjou, 2009; Solá and Griebenow, 2010) . Hence, glycoengineering has been successfully used to enhance the pharmacological and physiochemical properties for several proteins (Egrie et al., 2003; Perlman et al., 2003; Ceaglio et al., 2008; Song et al., 2014) . As an example, application of this strategy to recombinant human erythropoietin (rHuEPO) has resulted in the development of the US Food and Drug Administration (FDA)-approved darbepoetin alfa, a hyper-glycosylated analog of rHuEPO that contains two additional N-linked glycan, and a threefold increase in serum half-life with increased in vivo efficacy compared to rHuEPO (Egrie et al., 2003) .
The overall objective of this project is to characterize the rhIFN-β analogs that were suggested by the rational design approach described in Samoudi et al. 2015 . In previous studies, trial-and-error glycoengineering approaches were used normally to identify suitable position(s) in the peptide backbone for introducing a new glycosylation site(s). Trial-and error approaches are labor-intensive because all possible analogs must be constructed and experimentally examined. Samoudi et al. 2015 described a rational in silico procedure for designing novel hyper-glycosylated hIFN-β analogs with one additional N-glycosylation site by introducing an Asn-X-Thr/Ser sequon with the least effect on the 3D structure, stability and receptor binding, whilst ensuring the glycosylation process would be carried out efficiently. In the current work, the two computationally qualified rhIFN-β analogs, L6T and S75N, were constructed, codonoptimized for CHO cells, expressed in CHO cells, and evaluated experimentally in parallel with the CHO cell codon-optimized version of the natural human sequence IFN-β (Opt-hIFN-β) to confirm the in silico methodology. Moreover, the effect of exogenous glycans on aggregation status of the hyper-glycosylated rhIFN-β analogs was investigated and compared to the Opt-hIFN-β produced under similar conditions.
Materials and methods

In silico design for identification of suitable N-glycosylation sites
The complete in silico approach for identification of suitable N-glycosylation sites was described in details previously (Samoudi et al., 2015) . In brief, three strategies were used to select positions for insertion of the additional Asn-X-Thr/Ser sequon: (i) minimize sequence changes, (ii) minimize structural alterations and (iii) find potential positions which could be efficiently glycosylated. Forty sites within the protein were identified and examined based on the 3D crystallographic structure of rhIFN-β (PDB code: 1AU1) and literatures review to recognize non-structural and non-functional residues (Karpusas et al., 1997 Runkel et al., 1998; Runkel et al., 2000) . The glycosylation probability for each site was evaluated by the NetNGlyc1.0 server (Gupta et al., 2005) . Analogs that had high glycosylation efficiency and no known mutational issues were selected for further structural analyses. The 3D structures were generated by comparative modeling using MODELLER (Eswar et al., 2006) with the crystal structure of rhIFN-β (PDB code: 1AU1, chain A) as the template (Karpusas et al., 1997) . Stereochemical parameters and the quality of the generated model were analyzed by several programs from SAVES (PROCHECK (Laskowski et al., 1993) , WHAT_CHECK (Hooft et al., 1996) , ERRAT (Colovos and Yeates, 1993) and VERIFY 3D (Liithy et al., 1992) ). Dynamics behavior of the analogs was investigated using GROMACS 4.5.3 package (Berendsen et al., 1995) with the OPLS-AA force field (Jorgenson and Tirado-Rives, 1988) . The Root Mean Square Deviation (RMSD) and Radius of Gyration (R gyr) values were calculated over the course of the simulations for the analogs to assess the impact of the mutation(s) on the molecular stability. The Root Mean Square Fluctuation (RMSF) values were calculated during simulations to assess the molecular flexibility. Solvent accessibility of the Asn residue within the analogs at the new N-glycosylation site was assessed using ASAview server (Ahmad et al., 2004) . And, the degree of structural similarity of the analogs to the natural hIFN-β was calculated using Swiss PDB Viewer (Guex and Peitsch, 1997) . Weightings were assigned the constraints, and the two analogs, L6T and S75N, were finally selected for experimental validation as both of molecules had the best overall characteristics scores (Samoudi et al., 2015) .
Construction of expression vectors for Opt-IFN-β and two rhIFN-β analogs
The cDNA sequence for the hIFN-β was obtained from UniProt (UniProt KB: P01574). The analog sequences were obtained by replacing corresponding codons in the hIFN-β sequence. All sequences were then codon-optimized for protein expression in CHO cells using GeneArt® Strings™ DNA Fragments service (ThermoFisher Scientific). The CHO cell codon-optimized rhIFN-β is termed Opt-IFN-β, and two codon-optimized analogs are termed S75N and L6T. Kozak consensus sequence with an ATG initiation codon for proper initiation of translation as well as the HindIII recognition site were added at the 5′ end of the sequences. An additional codon stop and the XhoI recognition site were also added at the 3′ end of sequences. All sequences were screened by Webcutter server (http://rna.lundberg. gu.se/cutter2/), to ensure that there is no recognition site for the enzymes used in cloning. The resulting sequences were then synthesized using GeneArt ® Strings™ DNA Fragments service. The gene products were digested with HindIII and XhoI restriction enzymes and ligated into HindIII-XhoI sites of pCEP4 mammalian expression vector under the control of constitutive CMV promoter (ThermoFisher Scientific). The sequences of all constructions were verified by high quality Sanger-style sequencing (Clemson University Genomics Computational Laboratory). All cloning steps and plasmid propagation were carried out in E. coli DH5α.
Cell line and culture condition
Plasmids containing cDNAs encoding the S75N and L6T analogs and Opt-IFN-β were expressed transiently using the FreeStyle™ MAX CHO expression system (ThermoFisher Scientific). This expression system is a serum-free platform that uses cationic lipidbased transfection reagent, FreeStyle™ MAX Reagent, to transfect suspension FreeStyle™ CHO-S ® cells. The CHO-S ® cells were cultured and transfected in 125 mL polycarbonate, disposable, sterile Erlenmeyer flask, containing 30 mL FreeStyle™ CHO Expression Medium, supplemented by 8 mM L-glutamine at 37°C in an 8% CO 2 atmosphere at 135 rpm. The transfection followed manufacture instructions, and included negative controls, no DNA and no FreeStyle™ MAX Reagent. The optimized DNA: FreeStyle™ MAX Reagent ratio was 32 µg/24 µL for a 30 mL culture. Cells were kept in FreeStyle™ CHO Expression Medium during transfection and protein production. Following transfection, samples were harvested from each culture every 24 h for up to Day 5. Cell concentrations and cell viability were measured by a TC20 automated cell counter (BioRad). Samples were collected in sterile tubes and centrifuge at 300 × g for 5 min at room temperature to remove cells, and the supernatant stored at −80°C for further analyses.
Purification
Cell-free samples were applied to the 1 mL Hi-Trap Blue column (GE Healthcare), which had been previously equilibrated with 20 mM sodium phosphate, 0.15 M NaCl buffer, pH 7.2 at a flow rate of 1 mL/min. The column was washed with approximately 5 column volumes (CV) of an equilibrium buffer solution. Then, 3 CV of a 20 mM sodium phosphate buffer solution (pH 7.2) containing 50% ethylene glycol was allowed to flow through the column at a flow rate of 0.5 mL/min to remove protein impurities. This washing step was followed by another washing step with 3 CV of an equilibrium buffer solution. Then, 3 CV of 20 mM sodium phosphate buffer solution (pH 7.2) containing 2 M NaCl was used with a flow rate of 0.5 mL/min. Next, 3 CV of 20 mM sodium phosphate buffer solution (pH 7.2) containing 2 M NaCl and 20% propylene glycol was used at 0.5 mL/min. Then, 3 CV of an elution buffer solution (20 mM sodium phosphate buffer solution containing 2 M NaCl and 50% propylene glycol, pH 7.2) was used at 0.5 mL/min to recover the protein. Fractions were analyzed by Dot blots. The protein containing fractions were then pooled and concentrated with an Amicon® Ultra Centrifugal Filter Devices (10Kcut-off, Millipore). Samples were reconstituted in PBS with 2% glycerol and stored at −20°C for further analyses.
SDS-PAGE, Western blotting and dot blotting analyses
SDS-PAGE analysis was performed according to the standard method using a Mini-PROTEIN ® Tetra Cell system with 4-15% polyacrylamide resolving gels (BioRad). Samples were pre-boiled for 5 min in loading buffer, and the electrophoresis was carried out at 200 V for~50 min. Gels were stained with the Silver Stain Kit (BioRad). The gels were also trans-blotted to the PVDF membrane using Mini Trans-Blot Electrophoretic Transfer Cell (BioRad). The membrane was allowed to dry completely and then blocked with non-fat milk (5%, w/v, in PBS containing 0.1% Tween 20) for 1 h. The blot was incubated with the 1:2000 dilution of monoclonal mouse anti-hIFN-β antibody (Chemicon; Catalog No: MAB416) for 1.5 h, followed by 1:6000 dilution of HRP-conjugated goat antimouse IgG antibody (BioRad; Catalog No: 170-6516) incubation. Immunoreactive bands were developed using Opti-4CN detection kit (BioRad). Washes were performed with PBS containing 0.1% (v/v) Tween 20 (PBS-T). Dilutions were prepared in PBS-T containing 1% (w/v) BSA. For Dot blot analysis, a grid was drawn on the nitrocellulose membrane (BioRad) with a pencil. The membrane became wet by slowly sliding it into the PBST and was dried on filter paper for approximately 5 min. Samples (5 µL) were transferred to the membrane by pipetting, and membrane was allowed to dry completely. Blocking, antibody incubations and signal visualization were then carried out by the same procedures as the Western blotting.
Enzymatic deglycosylation
Culture supernatants containing the rhIFN-β analogs (S75N or L6T) or Opt-IFN-β were subjected to enzymatic deglycosylation using a PNGase F kit (Biolabs Inc., UK) under denaturing condition. About 18 µL of supernatant were mixed with 2 µL of 10X Glycoprotein Denaturing Buffer then boiled for 10 min. Denatured glycoproteins were chilled on ice and the droplets were pulled down by centrifugation in a microspin for 10 s. For enzymatic deglycosylation, 4 µL 10X G7 Reaction Buffer, 4 µL 10% NP40 and 12 µl H 2 O was added to 20 µL denatured glycoprotein solution. Then 2 µL PNGase F was added, mixed gently, incubated at 37°C for 1 h, and then analyzed by Western blot.
Quantification
Enzyme-linked immunosorbent assay (ELISA) was used to quantify and characterize the Opt-IFN-β and rhIFN-β analogs. Briefly, 96-well plates were coated with 200 ng/well of the capture polyclonal rabbit anti-hIFN-β antibody (Chemicon; Catalog No: AB1431) in 50 mM carbonate-bicarbonate buffer (pH 9.6) and incubated overnight at 4°C. Plates were washed with Tris-buffered saline (TBS) containing 0.1% Tween (TBS-T) (3X). Plates were blocked for 1.5 h at room temperature with 3% (w/v) BSA in TBS-T, and then washed with TBS-T. Plates were incubated at room temperature for 2 h with 1:2 serial dilutions of a rhIFN-β standard (Millipore) from 256 to 1 ng/mL or 1:30 dilution of unknown samples in TBS. The plates were incubated for 1 h at room temperature with the 1:1000 dilution of detection monoclonal mouse anti-hIFN-β antibody (Chemicon; Catalog No: MAB416), followed by addition of diluted 1:3000 goat anti-mouse IgG (H+L)-HRP conjugate (BioRad; Catalog No: 1721011). After 1 h incubation, plates were incubated with TMB (3,3′,5,5′-tetramethylbenzidine) substrate solution from Santa Cruz Biotechnology for 15 min, and the reactions were stopped by the addition of equal volume of stopping solution (1 M H 2 SO 4 ). The optical density was measured at 450 nm with a microplate reader (ThermoFisher Scientific). Antibody dilutions were prepared in TBS-T containing 3% (w/v) BSA. The samples were analyzed in duplicate.
Aggregation quantification
The behaviors of proteins in aggregation tendency were investigated under the heat-induced aggregation stress. One set of samples was heated for 10 min at 79°C in 1.5 mL Eppendorf tubes, and cooled back to room temperature prior to ELISA. The loss of ELISA signal is proportional to the amount of aggregation state in a complex because the epitope becomes unavailable for antibody binding (Rodriguez et al., 2010) . The aggregation percentage was determined from the ELISA signal of heated and non-heated samples as follows (Equation (1) In vitro biological activity assay Biological activity of samples was determined using in vitro antiproliferative assay. Serial 1:2 dilutions of test samples in assay medium were added to 96-well plates, initially at 1000 ng/mL. A549 cells were then seeded into the wells, at 4000 cells/well in complete Ham's F-12K medium (ThermoFisher Scientific) containing 2 mM L-glutamine and 10% fetal bovine serum. Plates were incubated at 37°C for 96 h, and cell proliferation was measured using CellTiter 96 TM AQueous Non-Radioactive Cell Proliferation Assay (Promega).
Absorbance was read at 492 nm using a microplate reader. All samples were analyzed in duplicate. The half maximum effective concentration (EC50) for each protein was determined by fitting a sigmoidal curve to the dose-response using the following Equation (2) (Roisman et al., 2005) :
where y is the absorbance, and A 0 , A, c and s are the offset, amplitude, concentration and slope, respectively.
Statistical analysis
Differences between groups were compared by one-way ANOVA (P ≤ 0.05) followed by LSD Post hoc analysis, as appropriate.
Results
Identification of suitable N-glycosylation sites using an in silico approach Selection of suitable position(s) to introduce new N-glycosylation consensus sequences (Asn, X, Thr/Ser) in the protein backbone is challenging. Such a modification must not impact the 3D structure, stability and receptor-ligand interaction of the protein, and factors such as surface accessibility of the N-linked Asn residue and probability of the enzymatic glycosylation of the new N-glycosylation site must also be taken into account (Sinclair and Elliott, 2005) . The results of our previous work described a completely in silico strategy to identify suitable N-glycosylation sites (Samoudi et al., 2015) . We identified six hIFN-β analogs (L6T, S75N, D110N, M117N , Q46N-Q48T and Q49N-Q51T) that meet the 3D structure stability, molecular flexibility, glycosylation site occupancy probability and ligand-receptor interaction constraints. Additionally, the L6T analog had the highest probability of glycosylation among other qualified analogs, which represents an important aspect for the glycoengineering. In addition, the existence of a new N-glycosylation site at the N-terminal (Asn-4) is beneficial for L6T because it potentially could improve the state of post-translational modifications and secretion (Liu et al., 2009) . S75N was another interesting analog where the additional site is located very near the natural glycosylation site, the Asn-80 residue. This close proximity of the glycans might be beneficial to avoid possible contact inhibition by the new glycans during the receptor-IFN-β binding process. Moreover, the Asn residue is fully exposed in S75N analog which could be advantageous for folding and 3D structure as well as masking hydrophobic patches on the molecule surface. Of the six analogs, the L6T and S75N were therefore selected to be expressed in CHO cells for experimental validation (Samoudi et al., 2015) .
Expression and characterization of Opt-IFN-β and rhIFN-β analogs
The L6T, S75N, and Opt-hIFN-β sequences were codon-optimized and synthesized for expression in CHO cells using GeneArt® Strings™ DNA Fragments service. Alignment of these sequences is shown in Fig. 1 along with the intact hIFN-β sequence. Expression levels of the analogs and Opt-IFN-β in the culture media was obtained by ELISA every 24 h post-transfection. The results indicated that the analogs and Opt-IFN-β have roughly the similar secretion level in CHO cultures within the 3 days post-transfection (Table I) .
Expression of Opt-IFN-β and analogs was also assayed by Western blot (Fig. 2) . For Opt-IFN-β, two prominent bands were observed with molecular weight of 18 and~25 kDa which correlate with the non-glycosylated protein and N-glycosylated molecules, respectively. Above the 25 kDa band, there is a less distinct band and a defuse band. These bands correlate with heterogeneous glycan moieties. The rhIFN-β standard (Millipore) does not have an 18 kDa band corresponding to the non-glycosylated rhIFN-β, but does have a~25 kDa band with a high molecular weight smear, very similar to the Opt-IFN-β. For both the S75N and L6T analogs, there are distinct 18 kDa bands, which correspond to non-glycosylated protein; however, there is a much larger fraction of the proteins detected in the 25 kDa and higher molecular weight bands, which are distinctly different from the Opt-IFN-β and rhIFN-β standard banding patterns. Specifically, L6T and S75N have diffused bands with molecular weights ranging from 25 to~35 kDa. The higher molecular weight bands for L6T and S75N are consistent with the addition of a new glycosylation site and indicated the possibility of Nglycosylation of new glycoengineered positions on both analogs. To confirm that the high molecular weight bands for the analogs were due to N-linked glycans, the two analogs and Opt-IFN-β were enzymatically deglycosylated with PNGase F and analyzed by Western blot analysis. As shown in Fig. 3 , only one band at 18 kDa is present for the enzymatically treated L6T, S75N and Opt-IFN-β. The rhIFN-β standard, purchased from Millipore, performed the same as the Opt-IFN-β when deglycosylated (Fig. 3) . These deglycosylation results confirm that the high molecular weight bands observed on the Western blots were due to glycan moieties, confirming the mass increase observed was due to the N-glycosylation. Nonetheless, further analyses by peptide digests or mass spectrometry analysis would be required to confirm the location of the observed additional glycans.
Aggregation studies IFN-β is well known to form aggregates under storage conditions, and additional glycan sites have been proposed as a means to decrease protein aggregation (Sinclair and Elliott, 2005, Song et al., 2014) . FDA allows accelerated stability testing for storage, where the storage temperature is increased to 40°C for 6 months to mimic long-term storage of new drug substances under Guidance for Industry Q1A(R2) (Food and Drug Administration, 2003) . Fazeli et al. showed IFN-β has more rapid aggregation at 70°C compared to 37°C and 25°C; however, even at 70°C, it took hours for the monomer to aggregate to 80%. (Fazeli et al., 2014) . Using their kinetic data to determine the activation energy for nucleation and aggregation growth, we were able to estimate a temperature that would induce approximately 80% aggregation of the 'native' IFN-β, Opt-IFN-β in this case, within approximately 10 min. This temperature was estimated to be 79°C. Therefore, the aggregation tendency of the isoforms S75N and L6T were compared to the Opt-IFN-β under accelerated heating condition, 79°C for 10 min. An ELISA method was developed that could quantify rhIFN-β aggregation on the order of nanograms. Aggregation was analyzed from duplicate samples taken from suspension cultures medium. The aggregation of Opt-IFN-β, S75N and L6T following the elevated temperature condition is shown in Fig. 4 . The Opt-IFN-β had an aggregation percentage of 86.2 ± 1.1%, where S75N and L6T had aggregation percentages of 71.5 ± 1.3% and 64 ± 0.5%, respectively. The one-way ANOVA analysis indicated that the observed differences for aggregation tendency reached statistical significance between the groups (F(2.3) = 77.847, P = 0.003). Post hoc analysis indicated that the aggregation of Opt-IFN-β was significantly different from both L6T and S75N (P = 0.001 and P = 0.005, respectively), and the aggregation between S75N and L6T was significantly different (P = 0.016). Thus, the L6T analog had the lowest tendency to aggregate under accelerated heating conditions. These results reflect a beneficial effect of the additional N-glycan on the tendency for aggregation.
In vitro biological activity assay
Activation of the Type I IFN receptor is known to induce an antiviral state and inhibit cell proliferation in some cell types (Meager, 2002) . These two effects are mediated by different sets of IFN inducible genes. Amino acid substitutions and/or carbohydrate addition may change the 3D structure of the molecule and interfere with the receptor-ligand interaction, and subsequently diminishes the biological activity. Thus, the biological activity of the two rhIFN-β analogs was examined in a cell proliferation assay. The proliferation of A549 cells, a human lung carcinoma cells, was examined after exposure to the Opt-IFN-β and the L6T and S75N rhIFN-β analogs that was serial diluted. Figure 5 shows the anti-proliferation doseresponse curves for Opt-IFN-β and two analogs. The antiproliferation activity for a protein is defined as the concentration which results in 50% inhibition of cell growth (EC50) (Roisman et al., 2005) . The calculated mean of EC50 values for Opt-IFN-β and the S75N and L6T analogs were 77.9 ± 5.2, 75.8 ± 4.6 and 68.4 ± 12.2 (ng/mL), respectively. The one-way ANOVA analysis determined there were no significant differences in anti-proliferative activity between the groups (F(2.3) = 0.381 and P = 0.712). These results indicate that the hyper-glycosylation did not significantly alter the anti-proliferation activity of the rhIFN-β analogs when compared to the Opt-IFN-β.
Discussion
The application of natural proteins has been limited because none were evolved to be used as therapeutics; thus, are not well-suited for long-term storage, encountering non-physiological conditions, or long-term stability within a person. Therefore, new strategies are being applied to enhance the physicochemical and pharmacological properties of these natural proteins to improve therapeutic efficacies.
In this study, a glycoengineering strategy was examined to enhance the solubility of rhIFN-β, as hydrophobic-mediated aggregation is the major problem encountered with the clinical application and production of this protein. The overall goal was to introduce one N-glycosylation site to the protein through a single-point mutation, with minimal structural distortion or function alteration. Out previously described rational methodology identified the two analogs that were characterized experimentally (Samoudi et al., 2015) . Western blot analysis demonstrated that both engineered analogs had increased mass and that the increased mass was due to the additional N-linked glycans. The observed glycan additions to the analog proteins was of great importance because the introduction of an N-linked glycosylation consensus tripeptide (Asn-Xaa-Ser/Thr) is not sufficient to ensure carbohydrate addition to a protein (Elliott et al., 2004) . More importantly, both analogs retained similar biological activity to the Opt-IFN-β despite the addition of the new N-linked glycans. Previous researchers have indicated that the incorporation of N-glycosylation sites can cause a reduction of the in vitro bioactivity by decreasing receptor-binding affinity, as a result of steric hindrance and charge-based repulsion imposed by carbohydrates and/or protein miss-folding (Sinclair and Elliott, 2005) . Therefore, the similar in vitro bioactivity and observed glycan additions suggest that the rational evaluation is valuable prior to designing novel glycoengineered analogs of therapeutically important proteins. Further, the protein quantification in the culture media indicated that the S75N and L6T analogs and the Opt-IFN-β had roughly similar concentration (Table 1) . These similar expression levels indicated that there were no major difficulties processing the hyper-glycosylated proteins due to the quality control system of the endoplasmic reticulum, which ensures export of properly folded and assembled proteins (Trombetta and Parodi, 2003; Kleizen and Braakman, 2004) . The close proximity of the N-terminal (N4) N-glycosylation site in L6T may also have been slightly beneficial, as reflected by the slightly higher level of L6T secretion (Table 1) , because the existence of glycosylation at N-terminal enhances the secretion of recombinant proteins (Liu et al., 2009) . However, it is obvious that such assumptions need to be validated by more experimental analyses. In this study, an ELISA-based technique was employed to measure the effects of the additional glycans on the aggregation tendency. The results showed that the hyper-glycosylated analogs had lower aggregation levels than the Opt-IFN-β protein under the accelerated heating aggregation conditions. The additional N-glycan appears to reduce aggregation, potentially by masking surface-exposed hydrophobic residues similarly to mechanism that occurs in the naturally glycosylated IFN-β 1a. Additional glycans can also decrease aggregation through the addition of sialic acid hydrophilic groups that sequentially increases molecular size and charge. This has been clearly shown for rhIFN-β where the glycosylated form had a lower aggregation tendency than the non-glycosylated one (Rodriguez et al., 2010) . The Western blot analysis of the Opt-IFN-β and the S75N and L6T rhIFN-β analogs showed multiple bands for each protein. Specifically, the Opt-IFN-β glycosylated bands match the standard rhIFN-β protein purchased from Millipore. The S75N and L6T analogs had dissimilar banding patterns from the both standard and Opt-IFN-β, including more bands with significantly higher molecular weights (Fig. 3) . These additional bands are indication of variable degrees of glycosylation with heterogeneous carbohydrates structures attached. Also, these results are consistent with previous reports that indicated the glycosylation site occupancy is influenced by its position in the backbone sequence (Sinclair and Elliott, 2005) . Further, these results indicate that the glycosylation contents of S75N, L6T and Opt-IFN-β are different from each other. These glycosylation differences can subsequently affect the physicochemical properties such as solubility which was observed in this work as between S75N, L6T and Opt-IFN-β.
In conclusion, this study produced and characterized two hyperglycosylated rhIFN-β analogs designed by a rational in silico strategy. The Western blot data is consistent with a difference in glycosylation of the glycoengineered analogs. ELISA assays demonstrated that the analogs had decreased aggregation, and biological in vitro assays demonstrated that the analogs had retained activity. The results showed that a rational approach to glycoengineering design is a powerful tool to streamline the development and screening of glycoengineered proteins. Albeit, further studies are still necessary to confirm the impact of the rationally designed additional glycosylation sites on in vivo efficacy. Hyper-glycosylation has the potential to provide many benefits to a therapeutic protein, such as reducing immunogenicity.
The additional carbohydrates can also provide increases in protein solubility and stability, which in turn may reduce the possibility of aggregate formation (Sinclair and Elliott, 2005) . Aggregation has been implicated to increase immunogenicity of many proteins; however, to reduce aggregation, the number of potential N-glycosylation sites to which oligosaccharides can be attached is restricted (Ceaglio et al., 2008) . Indeed, the potential benefit of the addition of any glycan must be balanced by all the potential negative impacts on biological activity. The use of a molecular simulation approach allows one the more rapidly screen all possible N-glycan attached site, evaluate steric hindrance, protein folding stability and receptor access to identify candidate isoforms and produce for a full evaluation.
